Table 2.
Baseline characteristics.
| Characteristics | Intervention group, N = 71, n (%) | Control group, N = 71, n (%) | |
|---|---|---|---|
| Age | Median (range) | 75 (70–85) | 75 (70–88) |
| Sex | Men | 43 (61) | 38 (54) |
| Women | 28 (39) | 33 (46) | |
| PS | 0 | 32 (45) | 34 (48) |
| 1 | 32 (45) | 32 (45) | |
| ≥2 | 7 (10) | 5 (7.0) | |
| Civil status | Single | 26 (37) | 22 (31) |
| Living together | 45 (63) | 49 (69) | |
| BMI | Median (range) | 25 (16.8–37.2) | 23.3 (16.5–33.6) |
| Comorbidity | 0–4 | 11 (15) | 20 (28) |
| CIRS-G score | 5–7 | 31 (44) | 26 (37) |
| ≥8 | 29 (41) | 25 (35) | |
| G8 score | Median (range) | 12 (7–14) | 12 (6–14) |
| Number of medications | 0 | 2 (3) | 6 (8.4) |
| 1–3 | 33 (47) | 24 (34) | |
| 4–5 | 19 (28) | 22 (31) | |
| 6+ | 17 (24) | 19 (27) | |
| Treatment setting | Adjuvant | 40 (56) | 37 (52) |
| Palliative | 22 (31) | 22 (31) | |
| Downstaging | 7 (10) | 8 (11) | |
| Adjuvant after metastatic surgery | 2 (3) | 4 (5.6) | |
| Start dose | Full | 27 (38) | 30 (42) |
| Primary dose reduction | 44 (62) | 41 (58) | |
| Tumour location | Right colon | 32 (45) | 31 (44) |
| Left colon | 25 (35) | 29 (41) | |
| Rectum | 14 (20) | 11 (16) | |
| CT regimen length adjuvant setting | 3 months | 0 (0) | 3 (8) |
| 6 months | 4 (100) | 34 (92) | |
| CT regimen (all patients) | Capecitabine/5-FU | 21 (29.6) | 26 (37) |
| Capeox/Folfox | 35 (49.3) | 23 (32) | |
| Capiri/Folfiri | 15 (21.1) | 22 (31) | |
| CT regimen | Capecitabine/5-FU | 15 (37.5) | 19 (51) |
| Adjuvant setting | Capeox/Folfox | 25 (62.5) | 18 (49) |
| CT regimen | Capecitabine/5-FU | 6 (27.3) | 5 (23) |
| Palliative setting | Capeox/Folfox | 4 (18.2) | 2 (9.1) |
| Capiri/Folfiri | 12 (54.5) | 15 (68) | |
| MSI | MSI stable | 56 (79) | 57 (80) |
| MSI unstable | 9 (13) | 11 (16) | |
| Not known | 6 (8) | 3 (4.2) | |
| KRAS status | Mutation | 39 (55) | 26 (37) |
| No mutation | 28 (40) | 44 (62) | |
| Not known | 4 (6) | 1 (1) | |
| NRAS status | Mutation | 3 (4) | 4 (5.6) |
| No mutation | 58 (82) | 52 (73) | |
| Not known | 10 (14) | 15 (21) | |
| BRAF status | Mutation | 16 (23) | 12 (17) |
| No mutation | 45 (63) | 44 (62) | |
| Not known | 10 (14) | 15 (21) |
BMI body mass index, CT chemotherapy, MSI microsatellite instability, PS ECOG performance status.